Gout

🏷

Classifications

Harrison's Part

⚙

Pathophysiology

6

Hyperuricemia

Elevated serum uric acid from increased purine metabolism or decreased renal excretion leads to supersaturation and crystal formation. Urate is the end product of purine catabolism in humans.

SLC2A9 hgnc:13446 ABCG2 hgnc:74 SLC22A12 hgnc:17989

Purine Metabolism GO:0006144 ↑ INCREASED Urate metabolic process GO:0046415 ↑ INCREASED Purine nucleotide catabolic process GO:0006195 ↑ INCREASED

Computational models

Minimal Urate Homeostasis Model KINETIC Antimony/tellurium Serum urate is the model's single state; it rises above the ~6.8 mg/dL solubility limit under reduced fractional excretion (ABCG2 loss, low f_exc) or increased purine load (HPRT1 loss, PRPS1 superactivity), and is lowered by xanthine-oxidase inhibitors, uricosurics, and uricase.

Downstream

Crystal Deposition Sustained hyperuricemia drives serum urate beyond its saturation point, promoting nucleation and deposition of monosodium urate crystals in joints and soft tissues.

Nephrolithiasis Sustained hyperuricemia and hyperuricosuria, together with low urinary pH, promote uric acid supersaturation and crystallization in the renal collecting system, producing uric acid nephrolithiasis. This renal stone pathway is mechanistically distinct from articular monosodium urate deposition.

Show evidence (1 reference)

PMID:38972919 SUPPORT

"Crystallization of monosodium urate monohydrate (MSU) leads to painful gouty arthritis."

Establishes that hyperuricemia-driven MSU crystallization is the fundamental pathological process in gout.

Crystal Deposition

Monosodium urate (MSU) crystals deposit in joints and soft tissues when serum urate exceeds saturation point (~6.8 mg/dL). Crystals trigger inflammatory response.

Downstream

Inflammasome Activation Deposited MSU crystals are phagocytosed by resident macrophages, triggering NLRP3 inflammasome activation and the acute inflammatory cascade.

Show evidence (2 references)

PMID:38972919 SUPPORT

"inflammatory MSU crystals form after a non-inflammatory amorphous precursor (AMSU) that nucleates heterogeneously on collagen fibrils from damaged articular cartilage of gout patients"

Describes the non-classical crystallization pathway where MSU forms via an amorphous precursor on damaged cartilage collagen, explaining the anatomical specificity of crystal deposition.

PMID:38972919 SUPPORT

"This non-classical crystallization route imprints a nanogranular structure to biogenic acicular MSU crystals, which have smaller unit cell volume, lower microstrain, and higher crystallinity than synthetic MSU."

Characterizes the unique structural properties of pathological MSU crystals that form in vivo at low supersaturation over extended time periods.

Inflammasome Activation

MSU crystals are phagocytosed by macrophages, activating NLRP3 inflammasome and triggering IL-1beta release, driving acute inflammatory flare.

Macrophage CL:0000235

NLRP3 inflammasome complex assembly GO:0044546 ↑ INCREASED Interleukin-1 beta production GO:0032611 ↑ INCREASED Positive regulation of inflammatory response GO:0050729 ↑ INCREASED

NLRP3 inflammasome complex GO:0072559

Downstream

Neutrophil Recruitment IL-1beta and downstream cytokines/chemokines released after inflammasome activation recruit neutrophils to the joint, amplifying acute inflammation.

Complement Activation The inflammatory milieu around MSU crystals engages the complement system, with C5 among the key emergent inflammatory mediators.

Acute Arthritis Macrophage NLRP3 inflammasome activation initiates the acute gouty inflammatory flare manifesting as acute arthritis.

Show evidence (3 references)

PMID:39386881 SUPPORT

"Gout represents an autoinflammatory disorder instigated by monosodium urate crystals. Its primary manifestation involves the recruitment of diverse immune cell populations, including neutrophils and macrophages. Macrophages assume a pivotal role in the initiation of acute gouty inflammation and..."

Establishes the central role of macrophages in initiating and propagating the acute inflammatory response to MSU crystals in gout.

PMID:39386881 SUPPORT

"Macrophages, characterized by different subtypes, exhibit distinct functionalities that either contribute to the progression or regression of gout."

Demonstrates that macrophages have complex, context-dependent roles in both promoting and resolving gouty inflammation depending on their polarization state.

PMID:39426967 SUPPORT

"At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins (p < 0.05) in clustering and proteome networks in sera and peripheral blood mononuclear cells."

Shows that effective urate-lowering therapy modulates immune cell proteomes, including those relevant to inflammasome activation, correlating with reduced flare burden.

Neutrophil Recruitment

IL-1beta and other cytokines recruit neutrophils to the joint, amplifying inflammation and causing the intense pain and swelling of acute gout attacks.

Neutrophil CL:0000775

Neutrophil chemotaxis GO:0030593 ↑ INCREASED Inflammatory response GO:0006954 ↑ INCREASED

Downstream

Neutrophil Extracellular Trap Formation Recruited neutrophils exposed to MSU crystals form neutrophil extracellular traps (NETs) in the inflamed joint.

Joint Pain Neutrophil influx and amplified inflammation produce the intense joint pain of the acute gout attack.

Joint Swelling Neutrophil-amplified joint inflammation produces the swelling characteristic of the acute gout attack.

Show evidence (2 references)

PMID:39386881 SUPPORT

"Its primary manifestation involves the recruitment of diverse immune cell populations, including neutrophils and macrophages."

Confirms that neutrophil recruitment is a primary feature of the acute gouty inflammatory response.

PMID:39426967 SUPPORT

"In both cohorts, a treatment-emergent serum interactome included key gouty inflammation mediators (C5, IL-1B, CXCL8, IL6)."

Identifies IL-1B and CXCL8 as key mediators in the serum interactome associated with gouty inflammation, supporting their role in neutrophil recruitment and activation.

Complement Activation

MSU crystals activate the complement system, particularly C5, contributing to neutrophil recruitment and amplifying the inflammatory response. Effective urate-lowering therapy modulates complement and inflammatory protein networks.

Complement activation GO:0006956 ↑ INCREASED

Downstream

Neutrophil Recruitment Complement activation, including C5/C5a generation, contributes to neutrophil recruitment and amplification of the inflammatory response.

Show evidence (3 references)

PMID:39426967 SUPPORT

"Sera demonstrated altered complement activation and regulatory gene ontology biologic processes."

Demonstrates that complement activation pathways are altered in gout and modulated by effective urate-lowering therapy.

PMID:39426967 SUPPORT

"Reduced gout flares are linked with a XOI treatment-emergent serum protein interactome that includes inflammation regulators, associated with altered complement activation and regulatory biologic processes."

Shows that reduction in gout flares correlates with changes in complement activation pathways, establishing complement as a key therapeutic target and biomarker.

PMID:39426967 SUPPORT

"Last, febuxostat treatment decreased complement activation biologic process proteins in cultured BMDMs."

Provides mechanistic evidence that xanthine oxidase inhibitors directly modulate complement activation in macrophages beyond their urate-lowering effects.

Neutrophil Extracellular Trap Formation

Neutrophils form extracellular traps (NETs) in response to MSU crystals. NETs initially amplify inflammation but aggregated NETs (aggNETs) promote resolution by encapsulating crystals, degrading cytokines, and blocking further neutrophil recruitment. NETs also contribute to tophi formation.

Neutrophil CL:0000775

positive regulation of inflammatory response GO:0050729 ↑ INCREASED negative regulation of inflammatory response GO:0050728 ↑ INCREASED

Downstream

Acute Arthritis MSU-induced NETs initially exacerbate the acute inflammatory flare before aggregated NETs drive its self-limited resolution.

Show evidence (3 references)

PMID:38910565 SUPPORT

"Neutrophil extracellular traps (NETs) are formed by neutrophils in response to pathogen attack. During gout, NETs induced by MSU crystals exacerbate inflammation, and aggregated NETs (aggNETs) promote the resolution of gout-associated inflammation by encapsulating MSU crystals, degrading..."

Describes the dual role of NETs in gout - initially amplifying inflammation but then promoting resolution through aggregation and sequestration mechanisms.

PMID:38910565 SUPPORT

"With disease progression, NETs participate in the formation of tophi."

Establishes the role of NETs in chronic gout pathology, specifically in the formation of tophi (urate crystal deposits).

PMID:38910565 SUPPORT

"Therefore, aggNETs are a possible mechanism of spontaneous gout regression."

Identifies aggregated NETs as a key mechanism underlying the self-limited nature of acute gout flares and spontaneous resolution.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Genitourinary 1

Nephrolithiasis OCCASIONAL HP:0000787

Uric acid stones

Metabolism 1

Joint Swelling VERY_FREQUENT HP:0001386

Musculoskeletal 1

Acute Arthritis VERY_FREQUENT HP:0001369

Classically affects first MTP joint (podagra)

Show evidence (2 references)

PMID:38972919 SUPPORT

"Crystallization of monosodium urate monohydrate (MSU) leads to painful gouty arthritis."

Directly links MSU crystal formation to the development of painful acute arthritis in gout.

PMID:39386881 SUPPORT

"Macrophages assume a pivotal role in the initiation of acute gouty inflammation and subsequent inflammatory cascades."

Explains the cellular mechanism underlying acute arthritis through macrophage-mediated inflammatory cascade initiation.

Constitutional 1

Joint Pain VERY_FREQUENT Arthralgia HP:0002829

🧬

Genetic Associations

3

SLC2A9 (Risk Factor)

Gene: SLC2A9 hgnc:13446

ABCG2 (Risk Factor)

Gene: ABCG2 hgnc:74

SLC22A12 (Risk Factor)

Gene: SLC22A12 hgnc:17989

💊

Medical Actions

7

NSAIDs

First-line for acute flares (indomethacin, naproxen).

Show evidence (1 reference)

PMID:32391934 SUPPORT

"For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended."

The 2020 ACR guideline strongly recommends NSAIDs as first-line treatment for acute gout flares.

Colchicine

Effective for acute flares and prophylaxis.

Show evidence (1 reference)

PMID:32391934 SUPPORT

"For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended."

The 2020 ACR guideline strongly recommends colchicine as first-line treatment for acute gout flares.

Corticosteroids

Alternative for acute flares when NSAIDs contraindicated.

Show evidence (1 reference)

PMID:32391934 SUPPORT

"For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended."

The 2020 ACR guideline strongly recommends glucocorticoids as first-line treatment for acute gout flares.

Allopurinol

Xanthine oxidase inhibitor for urate-lowering therapy.

Show evidence (3 references)

PMID:39426967 SUPPORT

"Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors (XOIs) paradoxically causes early increase in gouty arthritis flares."

Describes the paradoxical early flare phenomenon with XOI treatment, an important clinical consideration.

PMID:39426967 SUPPORT

"At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins (p < 0.05) in clustering and proteome networks in sera and peripheral blood mononuclear cells."

Demonstrates that sustained XOI urate-lowering therapy normalizes serum urate and reduces flares through modulation of immune proteomes.

PMID:32391934 SUPPORT Other

"allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease"

The 2020 ACR guideline strongly recommends allopurinol as the preferred first-line urate-lowering therapy, including in moderate-to-severe chronic kidney disease.

Febuxostat

Alternative xanthine oxidase inhibitor.

Show evidence (1 reference)

PMID:39426967 SUPPORT

"Last, febuxostat treatment decreased complement activation biologic process proteins in cultured BMDMs."

Shows that febuxostat has anti-inflammatory effects beyond urate lowering by modulating complement activation in macrophages.

Probenecid

Uricosuric agent increasing renal urate excretion.

Pegloticase

Recombinant uricase for refractory gout.

🌍

Environmental Factors

6

Red Meat and Organ Meat Intake

Purine-rich mammalian meat raises urate burden

Show evidence (1 reference)

PMID:15014182 SUPPORT Human Clinical

"Higher levels of meat and seafood consumption are associated with an increased risk of gout"

12-year prospective cohort of 47,150 men; highest versus lowest quintile of meat intake carried a multivariate relative risk of 1.41. The same study found purine-rich vegetables were not associated with risk, so the annotation's purine framing is specific to animal sources.

Shellfish Intake

Purine-rich shellfish can precipitate hyperuricemia and flares

Show evidence (1 reference)

PMID:15014182 SUPPORT Human Clinical

"Higher levels of meat and seafood consumption are associated with an increased risk of gout"

Seafood intake carried a relative risk of 1.51 for incident gout. PARTIAL because the cohort measured incident gout rather than precipitation of flares in established disease.

Beer Intake

Beer or cider carries the strongest per-drink association with incident gout among the beverages compared

Show evidence (1 reference)

PMID:39196557 SUPPORT Human Clinical

"with beer or cider showing the strongest association per 1 pint per day"

UK Biobank cohort of 401,128 participants; beer or cider had the strongest per-unit association with incident gout among the beverages compared (champagne/white wine, beer or cider, spirits), in both sexes. The source measures beer and cider as one category and does not separate them.

Fructose-Sweetened Soft Drink Intake

Fructose-containing soft drinks increase urate production

Show evidence (1 reference)

PMID:31061018 SUPPORT Human Clinical

"There is an adverse association of SSB and fruit juice intake with incident gout"

Meta-analysis of prospective cohorts (RR 2.08 for sugar-sweetened beverages); the association did not extend to whole fruit, which is why the exposure is scoped to soft drinks.

Dehydration

Concentrates urate

Diuretics

Reduce urate excretion

Show evidence (1 reference)

PMID:22031222 SUPPORT Human Clinical

"Thiazide and loop diuretics were associated with increased gout risk, an association mediated by a change in serum urate levels"

Prospective cohort establishing both the gout risk and that it is mediated by a rise in serum urate, which is the mechanism this annotation records.

🔬

Biochemical Markers

3

Serum Uric Acid (Elevated)

Context: Usually >6.8 mg/dL, may be normal during acute attack

Pathograph Readouts

Pharmacodynamic Marker Of Hyperuricemia Positive Pharmacodynamic

Higher serum uric acid tracks the hyperuricemic biochemical state that drives urate crystal supersaturation; reduction under xanthine oxidase inhibitors, URAT1 inhibitors, or uricase reports pharmacodynamic urate-lowering in gout.

FDA-SE-adult-noncancer-029 FDA

Serum uric acid

Traditional Validated Surrogate Endpoint

Patients with gout

Show evidence (1 reference)

PMID:39426967 SUPPORT Human Clinical

"At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins"

Supports serum urate normalization as a pharmacodynamic readout of urate-lowering therapy in gout.

Reference Ranges

Urate [Mass/volume] in Serum or Plasma 3.5–7.2 mg/dL (adult males and postmenopausal women)

Urate-lowering target met (–6.0 mg/dL) Above target, below saturation (6.0–6.8 mg/dL) Hyperuricemia (supersaturated) (6.8– mg/dL) → Hyperuricemia

Urate-lowering target met: Below the <6.0 mg/dL serum-urate target recommended for gout; sustained levels here favor dissolution of existing monosodium urate deposits.

Above target, below saturation: Above the recommended urate-lowering target but below the monosodium urate saturation point; a suboptimal intermediate range in gout.

Hyperuricemia (supersaturated): Exceeds the monosodium urate saturation threshold, promoting crystal nucleation and deposition that drives gout.

The <6.0 mg/dL urate-lowering target follows Desideri et al. 2014 and Chen et al. 2018; ~6.8 mg/dL (~404 umol/L) is the widely cited physiologic monosodium urate saturation point at body temperature.

Show evidence (2 references)

PMID:24867507 SUPPORT Human Clinical

"serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal women and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries"

Establishes the conventional adult male / postmenopausal-female serum urate reference interval of 3.5-7.2 mg/dL.

PMID:30145637 SUPPORT Human Clinical

"A stricter threshold of serum urate (< 6.0 mg/dL) should be made"

Supports a stricter <6.0 mg/dL serum-urate target for protection against gout.

Urate [Mass/volume] in Serum or Plasma 2.6–6.0 mg/dL (premenopausal women)

Normal (2.6–6.0 mg/dL) Hyperuricemia (6.0– mg/dL) → Hyperuricemia

Hyperuricemia: Above the upper reference limit for premenopausal women.

Show evidence (1 reference)

PMID:24867507 SUPPORT Human Clinical

"serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal women and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries"

Establishes the lower premenopausal-female serum urate reference interval of 2.6-6.0 mg/dL.

Urate [Moles/volume] in Serum or Plasma –500.0 umol/L (boys 13-17 years (China, normal-weight))

Normal (–500.0 umol/L) High SUA (hyperuricemia screen) (500.0– umol/L) → Hyperuricemia

High SUA (hyperuricemia screen): Exceeds the P90 simplified high-SUA cut-off for boys aged 13-17 years.

Pediatric age/sex P90 high-SUA cut-offs (Zhu et al. 2026): boys >360 (6-9y), >400 (10-12y), >500 umol/L (13-17y); girls >350, >380, >400 umol/L.

Show evidence (1 reference)

PMID:41917945 SUPPORT Human Clinical

"for boys, > 360 μmol/L (ages 6-9), > 400 μmol/L (ages 10-12), and > 500 μmol/L (ages 13-17); for girls, > 350 μmol/L, > 380 μmol/L, and > 400 μmol/L"

National survey-derived P90 simplified cut-offs for high serum uric acid; boys 13-17 years are above the reference above 500 umol/L.

CRP (Elevated)

Context: Acute flare

Synovial Fluid Crystals (Present)

Context: Negatively birefringent MSU crystals diagnostic

🧮

Computational Models

1

Minimal Urate Homeostasis Model SBML Antimony/tellurium KINETIC

A single-compartment ODE model of serum urate as the balance of production (purine turnover processed by xanthine oxidase) and elimination (renal/gut fractional excretion plus uricase activity), authored for dismech-perturb (like the CKD-MBD Antimony component; not a BioModels deposit). Calibrated to a normal serum urate of ~5 mg/dL with the monosodium-urate solubility limit (~6.8 mg/dL) as the hyperuricemia threshold. Reducing fractional excretion reproduces underexcretion hyperuricemia (>90% of primary cases); raising purine load reproduces overproduction. Urate-lowering therapies act on distinct nodes: xanthine-oxidase inhibitors reduce production, uricosurics raise excretion, and recombinant uricase adds direct urate degradation.

Variable	Model ID	Unit	Ontology Mappings	Phenotype Thresholds
Serum_Urate Serum urate (uric acid) concentration at steady state; the balance of production and elimination.	`U`	mg/dL		Hyperuricemia above 6.8 mild 6.8 moderate 9.0 severe 12.0 Hypouricemia below 0.5× baseline mild 0.5× baseline moderate 0.35× baseline severe 0.2× baseline

Simulation results — 13 scenarios run with dismech-perturb (tellurium / libRoadRunner CVODE) over 500 h; baseline f_exc = 1.0

Scenario	Serum_Urate (mg/dL)	Activated phenotypes
Healthy baseline f_exc = 1.0	4.995005	reference
Underexcretion hyperuricemia (f_exc=0.5) drives Hyperuricemia	9.98004 2.00× baseline	Hyperuricemia · moderate
Severe underexcretion (f_exc=0.35) drives Hyperuricemia	14.245014 2.85× baseline	Hyperuricemia · severe
Urate overproduction (purine load) drives Hyperuricemia	12.487512 2.50× baseline	Hyperuricemia · severe
HPRT1 loss-of-function (overproduction; Lesch-Nyhan) drives Hyperuricemia	12.487512 2.50× baseline	Hyperuricemia · severe
PRPS1 superactivity (overproduction) drives Hyperuricemia	12.487512 2.50× baseline	Hyperuricemia · severe
ABCG2 loss-of-function (reduced excretion) drives Hyperuricemia	9.98004 2.00× baseline	Hyperuricemia · moderate
SLC2A9/GLUT9 loss-of-function (renal hypouricemia; protective) drives Hyperuricemia	1.666111 0.33× baseline	Hypouricemia · moderate
SLC22A12/URAT1 loss-of-function (renal hypouricemia; protective) drives Hyperuricemia	1.9992 0.40× baseline	Hypouricemia · mild
Allopurinol (xanthine oxidase inhibitor) drives Hyperuricemia	3.493014 0.70× baseline	none
Febuxostat (potent xanthine oxidase inhibitor) drives Hyperuricemia	2.49501 0.50× baseline	Hypouricemia · mild
Probenecid (uricosuric; increases excretion) drives Hyperuricemia	5.54939 1.11× baseline	none
Pegloticase (recombinant uricase; direct urate degradation) drives Hyperuricemia	3.846154 0.77× baseline	none
Allopurinol + probenecid (dual production + excretion) drives Hyperuricemia	3.121099 0.62× baseline	none

Derived artifact, regenerated by just gen-model-results — not curated evidence. Values rounded to 6 decimals. Config c6b1d8cb15c0, urate_homeostasis.xml a3eb6748f4bd. Phenotypes activate per the thresholds in the table above.

Pathograph links

Hyperuricemia Serum urate is the model's single state; it rises above the ~6.8 mg/dL solubility limit under reduced fractional excretion (ABCG2 loss, low f_exc) or increased purine load (HPRT1 loss, PRPS1 superactivity), and is lowered by xanthine-oxidase inhibitors, uricosurics, and uricase.

Findings

The monosodium-urate solubility limit (~6.8 mg/dL) defines the hyperuricemia threshold used for this model's Hyperuricemia phenotype mapping.

Show evidence (1 reference)

PMID:29904633 SUPPORT Other

"The solubility of uric acid at normal physiological pH is generally given as 6.8 mg/dL"

Provides the 6.8 mg/dL urate solubility limit used as the model's Hyperuricemia activation threshold.

Wired for dismech-perturb (models/urate_homeostasis.config.yaml; Antimony source models/urate_homeostasis.ant). The disease-severity dial is fractional excretion f_exc (baseline 1.0 = normal). Treatment scenarios model allopurinol and febuxostat (xanthine-oxidase inhibition, XO down), probenecid (uricosuric, f_exc up), and pegloticase (recombinant uricase, k_uricase up), plus a combination. URAT1/GLUT9 loss-of-function raise excretion (renal hypouricemia, protective), while ABCG2 loss lowers it. Thresholds use the ~6.8 mg/dL urate solubility limit; other bands are model-calibrated.

Show evidence (1 reference)

PMID:29904633 SUPPORT Other

"a progressive metabolic disease characterized by symptomatic hyperuricemia and deposition of monosodium urate (MSU) crystals in joints and soft tissues due to an imbalance in uric acid uptake, synthesis or excretion"

Establishes the production-versus-excretion imbalance that this single-compartment urate-balance model encodes.

{ }

Source YAML

click to show

name: Gout
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Gout results from chronic hyperuricemia, driven by increased purine turnover or reduced renal urate excretion through transporters such as ABCG2, SLC2A9, and SLC22A12.
  When serum urate exceeds saturation, monosodium urate crystals deposit in joints and soft tissues.
  Phagocytosed crystals activate the NLRP3 inflammasome and IL-1beta release, recruiting neutrophils and producing the intensely painful acute inflammatory arthritis of gout.
category: Complex
parents:
- Metabolic Disease
- Musculoskeletal Disease
disease_term:
  preferred_term: gout
  term:
    id: MONDO:0005393
    label: gout
pathophysiology:
- name: Hyperuricemia
  description: >
    Elevated serum uric acid from increased purine metabolism or decreased
    renal excretion leads to supersaturation and crystal formation.
    Urate is the end product of purine catabolism in humans.
  genes:
  - preferred_term: SLC2A9
    term:
      id: hgnc:13446
      label: SLC2A9
  - preferred_term: ABCG2
    term:
      id: hgnc:74
      label: ABCG2
  - preferred_term: SLC22A12
    term:
      id: hgnc:17989
      label: SLC22A12
  biological_processes:
  - preferred_term: Purine Metabolism
    term:
      id: GO:0006144
      label: purine nucleobase metabolic process
    modifier: INCREASED
  - preferred_term: Urate metabolic process
    term:
      id: GO:0046415
      label: urate metabolic process
    modifier: INCREASED
  - preferred_term: Purine nucleotide catabolic process
    term:
      id: GO:0006195
      label: purine nucleotide catabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:38972919
    reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
    supports: SUPPORT
    snippet: "Crystallization of monosodium urate monohydrate (MSU) leads to painful
      gouty arthritis."
    explanation: Establishes that hyperuricemia-driven MSU crystallization is
      the fundamental pathological process in gout.
  downstream:
  - target: Crystal Deposition
    description: >
      Sustained hyperuricemia drives serum urate beyond its saturation point,
      promoting nucleation and deposition of monosodium urate crystals in
      joints and soft tissues.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38972919
      reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
      supports: SUPPORT
      snippet: "Crystallization of monosodium urate monohydrate (MSU) leads to painful
        gouty arthritis."
      explanation: Establishes that hyperuricemia-driven MSU crystallization is
        the fundamental pathological process in gout.
  - target: Nephrolithiasis
    description: >
      Sustained hyperuricemia and hyperuricosuria, together with low urinary
      pH, promote uric acid supersaturation and crystallization in the renal
      collecting system, producing uric acid nephrolithiasis. This renal stone
      pathway is mechanistically distinct from articular monosodium urate
      deposition.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - hyperuricosuria
    - acidic urinary pH promoting uric acid crystallization
- name: Crystal Deposition
  description: >
    Monosodium urate (MSU) crystals deposit in joints and soft tissues
    when serum urate exceeds saturation point (~6.8 mg/dL). Crystals
    trigger inflammatory response.
  evidence:
  - reference: PMID:38972919
    reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
    supports: SUPPORT
    snippet: "inflammatory MSU crystals form after a non-inflammatory amorphous precursor
      (AMSU) that nucleates heterogeneously on collagen fibrils from damaged articular
      cartilage of gout patients"
    explanation: Describes the non-classical crystallization pathway where MSU
      forms via an amorphous precursor on damaged cartilage collagen, explaining
      the anatomical specificity of crystal deposition.
  - reference: PMID:38972919
    reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
    supports: SUPPORT
    snippet: "This non-classical crystallization route imprints a nanogranular structure
      to biogenic acicular MSU crystals, which have smaller unit cell volume, lower
      microstrain, and higher crystallinity than synthetic MSU."
    explanation: Characterizes the unique structural properties of pathological
      MSU crystals that form in vivo at low supersaturation over extended time
      periods.
  downstream:
  - target: Inflammasome Activation
    description: >
      Deposited MSU crystals are phagocytosed by resident macrophages, triggering
      NLRP3 inflammasome activation and the acute inflammatory cascade.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39386881
      reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
      supports: SUPPORT
      snippet: "Gout represents an autoinflammatory disorder instigated by monosodium
        urate crystals. Its primary manifestation involves the recruitment of diverse
        immune cell populations, including neutrophils and macrophages. Macrophages
        assume a pivotal role in the initiation of acute gouty inflammation and subsequent
        inflammatory cascades."
      explanation: Establishes that MSU crystals instigate macrophage-driven
        initiation of acute gouty inflammation.
- name: Inflammasome Activation
  conforms_to: "gout_urate_crystal_inflammation#NLRP3 Inflammasome Activation"
  description: >
    MSU crystals are phagocytosed by macrophages, activating NLRP3
    inflammasome and triggering IL-1beta release, driving acute
    inflammatory flare.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  cellular_components:
  - preferred_term: NLRP3 inflammasome complex
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
    modifier: INCREASED
  - preferred_term: Interleukin-1 beta production
    term:
      id: GO:0032611
      label: interleukin-1 beta production
    modifier: INCREASED
  - preferred_term: Positive regulation of inflammatory response
    term:
      id: GO:0050729
      label: positive regulation of inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:39386881
    reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
    supports: SUPPORT
    snippet: "Gout represents an autoinflammatory disorder instigated by monosodium
      urate crystals. Its primary manifestation involves the recruitment of diverse
      immune cell populations, including neutrophils and macrophages. Macrophages
      assume a pivotal role in the initiation of acute gouty inflammation and subsequent
      inflammatory cascades."
    explanation: Establishes the central role of macrophages in initiating and
      propagating the acute inflammatory response to MSU crystals in gout.
  - reference: PMID:39386881
    reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
    supports: SUPPORT
    snippet: "Macrophages, characterized by different subtypes, exhibit distinct functionalities
      that either contribute to the progression or regression of gout."
    explanation: Demonstrates that macrophages have complex, context-dependent
      roles in both promoting and resolving gouty inflammation depending on
      their polarization state.
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "At 48 weeks ULT, serum urate normalized in all gout patients, and flares
      declined in association with significantly altered proteins (p < 0.05) in clustering
      and proteome networks in sera and peripheral blood mononuclear cells."
    explanation: Shows that effective urate-lowering therapy modulates immune
      cell proteomes, including those relevant to inflammasome activation,
      correlating with reduced flare burden.
  downstream:
  - target: Neutrophil Recruitment
    description: >
      IL-1beta and downstream cytokines/chemokines released after inflammasome
      activation recruit neutrophils to the joint, amplifying acute inflammation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39426967
      reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
      supports: SUPPORT
      snippet: "In both cohorts, a treatment-emergent serum interactome included key
        gouty inflammation mediators (C5, IL-1B, CXCL8, IL6)."
      explanation: Identifies IL-1B and CXCL8 as key mediators linking inflammasome
        output to neutrophil recruitment in gouty inflammation.
  - target: Complement Activation
    description: >
      The inflammatory milieu around MSU crystals engages the complement system,
      with C5 among the key emergent inflammatory mediators.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - MSU crystal surface complement engagement
    evidence:
    - reference: PMID:39426967
      reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
      supports: SUPPORT
      snippet: "In both cohorts, a treatment-emergent serum interactome included key
        gouty inflammation mediators (C5, IL-1B, CXCL8, IL6)."
      explanation: Identifies C5 among the key emergent gouty inflammation mediators,
        linking the inflammatory response to complement activation.
  - target: Acute Arthritis
    description: >
      Macrophage NLRP3 inflammasome activation initiates the acute gouty
      inflammatory flare manifesting as acute arthritis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39386881
      reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
      supports: SUPPORT
      snippet: "Macrophages assume a pivotal role in the initiation of acute gouty inflammation
        and subsequent inflammatory cascades."
      explanation: Explains the cellular mechanism underlying acute arthritis
        through macrophage-mediated inflammatory cascade initiation.
- name: Neutrophil Recruitment
  description: >
    IL-1beta and other cytokines recruit neutrophils to the joint,
    amplifying inflammation and causing the intense pain and swelling
    of acute gout attacks.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: Neutrophil chemotaxis
    term:
      id: GO:0030593
      label: neutrophil chemotaxis
    modifier: INCREASED
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:39386881
    reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
    supports: SUPPORT
    snippet: "Its primary manifestation involves the recruitment of diverse immune
      cell populations, including neutrophils and macrophages."
    explanation: Confirms that neutrophil recruitment is a primary feature of
      the acute gouty inflammatory response.
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "In both cohorts, a treatment-emergent serum interactome included key
      gouty inflammation mediators (C5, IL-1B, CXCL8, IL6)."
    explanation: Identifies IL-1B and CXCL8 as key mediators in the serum
      interactome associated with gouty inflammation, supporting their role in
      neutrophil recruitment and activation.
  downstream:
  - target: Neutrophil Extracellular Trap Formation
    description: >
      Recruited neutrophils exposed to MSU crystals form neutrophil
      extracellular traps (NETs) in the inflamed joint.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38910565
      reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
      supports: SUPPORT
      snippet: "Neutrophil extracellular traps (NETs) are formed by neutrophils in response
        to pathogen attack. During gout, NETs induced by MSU crystals exacerbate inflammation,
        and aggregated NETs (aggNETs) promote the resolution of gout-associated inflammation
        by encapsulating MSU crystals, degrading cytokines and chemokines, and blocking
        the recruitment and activation of neutrophils."
      explanation: Establishes that MSU-recruited neutrophils form NETs during gout.
  - target: Joint Pain
    description: >
      Neutrophil influx and amplified inflammation produce the intense joint
      pain of the acute gout attack.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neutrophil-amplified acute joint inflammation
    evidence:
    - reference: PMID:39386881
      reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
      supports: SUPPORT
      snippet: "Its primary manifestation involves the recruitment of diverse immune
        cell populations, including neutrophils and macrophages."
      explanation: Links recruitment of neutrophils to the primary inflammatory
        manifestation of the acute gout attack.
  - target: Joint Swelling
    description: >
      Neutrophil-amplified joint inflammation produces the swelling
      characteristic of the acute gout attack.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neutrophil-amplified acute joint inflammation
    evidence:
    - reference: PMID:39386881
      reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
      supports: SUPPORT
      snippet: "Its primary manifestation involves the recruitment of diverse immune
        cell populations, including neutrophils and macrophages."
      explanation: Links neutrophil recruitment to the inflammatory joint
        manifestations of the acute gout attack.
- name: Complement Activation
  description: >
    MSU crystals activate the complement system, particularly C5, contributing
    to neutrophil recruitment and amplifying the inflammatory response.
    Effective urate-lowering therapy modulates complement and inflammatory
    protein networks.
  biological_processes:
  - preferred_term: Complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  evidence:
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "Sera demonstrated altered complement activation and regulatory gene
      ontology biologic processes."
    explanation: Demonstrates that complement activation pathways are altered in
      gout and modulated by effective urate-lowering therapy.
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "Reduced gout flares are linked with a XOI treatment-emergent serum protein
      interactome that includes inflammation regulators, associated with altered complement
      activation and regulatory biologic processes."
    explanation: Shows that reduction in gout flares correlates with changes in
      complement activation pathways, establishing complement as a key
      therapeutic target and biomarker.
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "Last, febuxostat treatment decreased complement activation biologic
      process proteins in cultured BMDMs."
    explanation: Provides mechanistic evidence that xanthine oxidase inhibitors
      directly modulate complement activation in macrophages beyond their
      urate-lowering effects.
  downstream:
  - target: Neutrophil Recruitment
    description: >
      Complement activation, including C5/C5a generation, contributes to
      neutrophil recruitment and amplification of the inflammatory response.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39426967
      reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
      supports: SUPPORT
      snippet: "Reduced gout flares are linked with a XOI treatment-emergent serum protein
        interactome that includes inflammation regulators, associated with altered complement
        activation and regulatory biologic processes."
      explanation: Links complement activation to the inflammation-regulator
        interactome that drives gouty flares and neutrophil-mediated inflammation.
- name: Neutrophil Extracellular Trap Formation
  description: >
    Neutrophils form extracellular traps (NETs) in response to MSU crystals.
    NETs initially amplify inflammation but aggregated NETs (aggNETs) promote
    resolution by encapsulating crystals, degrading cytokines, and blocking
    further neutrophil recruitment. NETs also contribute to tophi formation.
  biological_processes:
  - preferred_term: positive regulation of inflammatory response
    term:
      id: GO:0050729
      label: positive regulation of inflammatory response
    modifier: INCREASED
  - preferred_term: negative regulation of inflammatory response
    term:
      id: GO:0050728
      label: negative regulation of inflammatory response
    modifier: INCREASED
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  evidence:
  - reference: PMID:38910565
    reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
    supports: SUPPORT
    snippet: "Neutrophil extracellular traps (NETs) are formed by neutrophils in response
      to pathogen attack. During gout, NETs induced by MSU crystals exacerbate inflammation,
      and aggregated NETs (aggNETs) promote the resolution of gout-associated inflammation
      by encapsulating MSU crystals, degrading cytokines and chemokines, and blocking
      the recruitment and activation of neutrophils."
    explanation: Describes the dual role of NETs in gout - initially amplifying
      inflammation but then promoting resolution through aggregation and
      sequestration mechanisms.
  - reference: PMID:38910565
    reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
    supports: SUPPORT
    snippet: "With disease progression, NETs participate in the formation of tophi."
    explanation: Establishes the role of NETs in chronic gout pathology,
      specifically in the formation of tophi (urate crystal deposits).
  - reference: PMID:38910565
    reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
    supports: SUPPORT
    snippet: "Therefore, aggNETs are a possible mechanism of spontaneous gout regression."
    explanation: Identifies aggregated NETs as a key mechanism underlying the
      self-limited nature of acute gout flares and spontaneous resolution.
  downstream:
  - target: Acute Arthritis
    description: MSU-induced NETs initially exacerbate the acute inflammatory
      flare before aggregated NETs drive its self-limited resolution.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38910565
      reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
      supports: SUPPORT
      snippet: "During gout, NETs induced by MSU crystals exacerbate inflammation,"
      explanation: Supports NET-driven amplification of the acute gout
        inflammatory flare.
phenotypes:
- name: Acute Arthritis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Classically affects first MTP joint (podagra)
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: PMID:38972919
    reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
    supports: SUPPORT
    snippet: "Crystallization of monosodium urate monohydrate (MSU) leads to painful
      gouty arthritis."
    explanation: Directly links MSU crystal formation to the development of
      painful acute arthritis in gout.
  - reference: PMID:39386881
    reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
    supports: SUPPORT
    snippet: "Macrophages assume a pivotal role in the initiation of acute gouty inflammation
      and subsequent inflammatory cascades."
    explanation: Explains the cellular mechanism underlying acute arthritis
      through macrophage-mediated inflammatory cascade initiation.
- name: Joint Swelling
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Joint Swelling
    term:
      id: HP:0001386
      label: Joint swelling
- name: Joint Pain
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
- name: Nephrolithiasis
  category: Renal
  frequency: OCCASIONAL
  notes: Uric acid stones
  phenotype_term:
    preferred_term: Kidney Stones
    term:
      id: HP:0000787
      label: Nephrolithiasis
biochemical:
- name: Serum Uric Acid
  presence: Elevated
  context: Usually >6.8 mg/dL, may be normal during acute attack
  readouts:
  - target: Hyperuricemia
    relationship: PHARMACODYNAMIC_MARKER_OF
    direction: POSITIVE
    endpoint_context: PHARMACODYNAMIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-029
    interpretation: >-
      Higher serum uric acid tracks the hyperuricemic biochemical state that
      drives urate crystal supersaturation; reduction under xanthine oxidase
      inhibitors, URAT1 inhibitors, or uricase reports pharmacodynamic
      urate-lowering in gout.
    evidence:
    - reference: PMID:39426967
      reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        At 48 weeks ULT, serum urate normalized in all gout patients, and
        flares declined in association with significantly altered proteins
      explanation: >-
        Supports serum urate normalization as a pharmacodynamic readout of
        urate-lowering therapy in gout.
  biomarker_term:
    preferred_term: Serum Uric Acid Measurement
    term:
      id: NCIT:C61034
      label: Serum Uric Acid Measurement
  synonyms:
  - Serum urate
  - Uric acid
  reference_ranges:
  - loinc_term:
      id: LOINC:3084-1
      label: Urate [Mass/volume] in Serum or Plasma
    lower_bound: 3.5
    upper_bound: 7.2
    unit: mg/dL
    population: adult males and postmenopausal women
    evidence:
    - reference: PMID:24867507
      reference_title: "Is it time to revise the normal range of serum uric acid levels?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal women and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries"
      explanation: Establishes the conventional adult male / postmenopausal-female serum urate reference interval of 3.5-7.2 mg/dL.
    - reference: PMID:30145637
      reference_title: "The benchmark dose estimation of reference levels of serum urate for gout."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A stricter threshold of serum urate (< 6.0 mg/dL) should be made"
      explanation: Supports a stricter <6.0 mg/dL serum-urate target for protection against gout.
    interpretation_bands:
    - name: Urate-lowering target met
      upper_bound: 6.0
      unit: mg/dL
      abnormal_flag: NORMAL
      interpretation: >-
        Below the <6.0 mg/dL serum-urate target recommended for gout; sustained
        levels here favor dissolution of existing monosodium urate deposits.
    - name: Above target, below saturation
      lower_bound: 6.0
      upper_bound: 6.8
      unit: mg/dL
      abnormal_flag: HIGH
      interpretation: >-
        Above the recommended urate-lowering target but below the monosodium
        urate saturation point; a suboptimal intermediate range in gout.
    - name: Hyperuricemia (supersaturated)
      lower_bound: 6.8
      unit: mg/dL
      abnormal_flag: HIGH
      phenotype_term:
        preferred_term: Hyperuricemia
        term:
          id: HP:0002149
          label: Hyperuricemia
      interpretation: >-
        Exceeds the monosodium urate saturation threshold, promoting crystal
        nucleation and deposition that drives gout.
    notes: >-
      The <6.0 mg/dL urate-lowering target follows Desideri et al. 2014 and Chen
      et al. 2018; ~6.8 mg/dL (~404 umol/L) is the widely cited physiologic
      monosodium urate saturation point at body temperature.
  - loinc_term:
      id: LOINC:3084-1
      label: Urate [Mass/volume] in Serum or Plasma
    lower_bound: 2.6
    upper_bound: 6.0
    unit: mg/dL
    population: premenopausal women
    evidence:
    - reference: PMID:24867507
      reference_title: "Is it time to revise the normal range of serum uric acid levels?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal women and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries"
      explanation: Establishes the lower premenopausal-female serum urate reference interval of 2.6-6.0 mg/dL.
    interpretation_bands:
    - name: Normal
      lower_bound: 2.6
      upper_bound: 6.0
      unit: mg/dL
      abnormal_flag: NORMAL
    - name: Hyperuricemia
      lower_bound: 6.0
      unit: mg/dL
      abnormal_flag: HIGH
      phenotype_term:
        preferred_term: Hyperuricemia
        term:
          id: HP:0002149
          label: Hyperuricemia
      interpretation: Above the upper reference limit for premenopausal women.
  - loinc_term:
      id: LOINC:14933-6
      label: Urate [Moles/volume] in Serum or Plasma
    upper_bound: 500.0
    unit: umol/L
    population: boys 13-17 years (China, normal-weight)
    evidence:
    - reference: PMID:41917945
      reference_title: "Serum uric acid levels among children and adolescents in China: percentile reference values and national prevalence estimates of hyperuricemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "for boys, > 360 μmol/L (ages 6-9), > 400 μmol/L (ages 10-12), and > 500 μmol/L (ages 13-17); for girls, > 350 μmol/L, > 380 μmol/L, and > 400 μmol/L"
      explanation: National survey-derived P90 simplified cut-offs for high serum uric acid; boys 13-17 years are above the reference above 500 umol/L.
    interpretation_bands:
    - name: Normal
      upper_bound: 500.0
      unit: umol/L
      abnormal_flag: NORMAL
    - name: High SUA (hyperuricemia screen)
      lower_bound: 500.0
      unit: umol/L
      abnormal_flag: HIGH
      phenotype_term:
        preferred_term: Hyperuricemia
        term:
          id: HP:0002149
          label: Hyperuricemia
      interpretation: Exceeds the P90 simplified high-SUA cut-off for boys aged 13-17 years.
    notes: >-
      Pediatric age/sex P90 high-SUA cut-offs (Zhu et al. 2026): boys >360 (6-9y),
      >400 (10-12y), >500 umol/L (13-17y); girls >350, >380, >400 umol/L.
- name: CRP
  presence: Elevated
  context: Acute flare
- name: Synovial Fluid Crystals
  presence: Present
  context: Negatively birefringent MSU crystals diagnostic
genetic:
- name: SLC2A9
  gene_term:
    preferred_term: SLC2A9
    term:
      id: hgnc:13446
      label: SLC2A9
  association: Risk Factor
  notes: Major urate transporter
- name: ABCG2
  gene_term:
    preferred_term: ABCG2
    term:
      id: hgnc:74
      label: ABCG2
  association: Risk Factor
  notes: Urate efflux transporter
- name: SLC22A12
  gene_term:
    preferred_term: SLC22A12
    term:
      id: hgnc:17989
      label: SLC22A12
  association: Risk Factor
  notes: URAT1 urate reabsorption
environmental:
- name: Red Meat and Organ Meat Intake
  notes: Purine-rich mammalian meat raises urate burden
  food_source:
    preferred_term: mammalian meat food product
    term:
      id: FOODON:00001006
      label: mammalian meat food product
  evidence:
  - reference: PMID:15014182
    reference_title: Purine-rich foods, dairy and protein intake, and the risk of gout
      in men
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Higher levels of meat and seafood consumption are associated with an
      increased risk of gout
    explanation: 12-year prospective cohort of 47,150 men; highest versus lowest quintile
      of meat intake carried a multivariate relative risk of 1.41. The same study
      found purine-rich vegetables were not associated with risk, so the annotation's
      purine framing is specific to animal sources.
- name: Shellfish Intake
  notes: Purine-rich shellfish can precipitate hyperuricemia and flares
  food_source:
    preferred_term: shellfish food product
    term:
      id: FOODON:00001293
      label: shellfish food product
  evidence:
  - reference: PMID:15014182
    reference_title: Purine-rich foods, dairy and protein intake, and the risk of gout
      in men
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Higher levels of meat and seafood consumption are associated with an
      increased risk of gout
    explanation: Seafood intake carried a relative risk of 1.51 for incident gout.
      PARTIAL because the cohort measured incident gout rather than precipitation
      of flares in established disease.
- name: Beer Intake
  exposure_term:
    preferred_term: beer intake
    term:
      id: XCO:0000071
      label: beer
  notes: Beer or cider carries the strongest per-drink association with incident
    gout among the beverages compared
  food_source:
    preferred_term: beer beverage
    term:
      id: FOODON:00001260
      label: beer beverage
  evidence:
  - reference: PMID:39196557
    reference_title: Consumption of Total and Specific Alcoholic Beverages and Long-Term
      Risk of Gout Among Men and Women
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: with beer or cider showing the strongest association per 1 pint per day
    explanation: UK Biobank cohort of 401,128 participants; beer or cider had the
      strongest per-unit association with incident gout among the beverages compared
      (champagne/white wine, beer or cider, spirits), in both sexes. The source
      measures beer and cider as one category and does not separate them.
- name: Fructose-Sweetened Soft Drink Intake
  notes: Fructose-containing soft drinks increase urate production
  evidence:
  - reference: PMID:31061018
    reference_title: "Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There is an adverse association of SSB and fruit juice intake with incident
      gout
    explanation: Meta-analysis of prospective cohorts (RR 2.08 for sugar-sweetened
      beverages); the association did not extend to whole fruit, which is why the
      exposure is scoped to soft drinks.
- name: Dehydration
  exposure_term:
    preferred_term: dehydration
    term:
      id: XCO:0001602
      label: dehydration
  notes: Concentrates urate
  review_notes: Left deliberately uncited. Targeted PubMed searches (fluid intake
    and recurrent gout attacks; dehydration and serum urate; hydration status and
    hyperuricemia) returned no study whose abstract states this claim directly. Per
    the evidence SOP the claim is kept as a note rather than attached to an
    approximately-relevant citation.
- name: Diuretics
  notes: Reduce urate excretion
  evidence:
  - reference: PMID:22031222
    reference_title: "Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thiazide and loop diuretics were associated with increased gout risk,
      an association mediated by a change in serum urate levels
    explanation: Prospective cohort establishing both the gout risk and that it is
      mediated by a rise in serum urate, which is the mechanism this annotation records.
treatments:
- name: NSAIDs
  description: First-line for acute flares (indomethacin, naproxen).
  evidence:
  - reference: PMID:32391934
    reference_title: "2020 American College of Rheumatology Guideline for the Management of Gout."
    supports: SUPPORT
    snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
      drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
      recommended."
    explanation: The 2020 ACR guideline strongly recommends NSAIDs as first-line
      treatment for acute gout flares.
- name: Colchicine
  description: Effective for acute flares and prophylaxis.
  evidence:
  - reference: PMID:32391934
    reference_title: "2020 American College of Rheumatology Guideline for the Management of Gout."
    supports: SUPPORT
    snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
      drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
      recommended."
    explanation: The 2020 ACR guideline strongly recommends colchicine as first-line
      treatment for acute gout flares.
- name: Corticosteroids
  description: Alternative for acute flares when NSAIDs contraindicated.
  evidence:
  - reference: PMID:32391934
    reference_title: "2020 American College of Rheumatology Guideline for the Management of Gout."
    supports: SUPPORT
    snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
      drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
      recommended."
    explanation: The 2020 ACR guideline strongly recommends glucocorticoids as first-line
      treatment for acute gout flares.
- name: Allopurinol
  description: Xanthine oxidase inhibitor for urate-lowering therapy.
  evidence:
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors
      (XOIs) paradoxically causes early increase in gouty arthritis flares."
    explanation: Describes the paradoxical early flare phenomenon with XOI
      treatment, an important clinical consideration.
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "At 48 weeks ULT, serum urate normalized in all gout patients, and flares
      declined in association with significantly altered proteins (p < 0.05) in clustering
      and proteome networks in sera and peripheral blood mononuclear cells."
    explanation: Demonstrates that sustained XOI urate-lowering therapy
      normalizes serum urate and reduces flares through modulation of immune
      proteomes.
  - reference: PMID:32391934
    reference_title: 2020 American College of Rheumatology Guideline for the Management of Gout.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease"
    explanation: The 2020 ACR guideline strongly recommends allopurinol as the preferred first-line urate-lowering therapy, including in moderate-to-severe chronic kidney disease.
- name: Febuxostat
  description: Alternative xanthine oxidase inhibitor.
  evidence:
  - reference: PMID:39426967
    reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
    supports: SUPPORT
    snippet: "Last, febuxostat treatment decreased complement activation biologic
      process proteins in cultured BMDMs."
    explanation: Shows that febuxostat has anti-inflammatory effects beyond
      urate lowering by modulating complement activation in macrophages.
- name: Probenecid
  description: Uricosuric agent increasing renal urate excretion.
- name: Pegloticase
  description: Recombinant uricase for refractory gout.
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
computational_models:
- name: Minimal Urate Homeostasis Model
  description: >-
    A single-compartment ODE model of serum urate as the balance of production
    (purine turnover processed by xanthine oxidase) and elimination (renal/gut
    fractional excretion plus uricase activity), authored for dismech-perturb
    (like the CKD-MBD Antimony component; not a BioModels deposit). Calibrated to
    a normal serum urate of ~5 mg/dL with the monosodium-urate solubility limit
    (~6.8 mg/dL) as the hyperuricemia threshold. Reducing fractional excretion
    reproduces underexcretion hyperuricemia (>90% of primary cases); raising
    purine load reproduces overproduction. Urate-lowering therapies act on
    distinct nodes: xanthine-oxidase inhibitors reduce production, uricosurics
    raise excretion, and recombinant uricase adds direct urate degradation.
  model_type: KINETIC
  model_id: urate_homeostasis
  model_format: SBML
  model_software: Antimony/tellurium
  perturbations:
  - preferred_term: HPRT1
    term:
      id: hgnc:5157
      label: HPRT1
  - preferred_term: PRPS1
    term:
      id: hgnc:9462
      label: PRPS1
  - preferred_term: ABCG2
    term:
      id: hgnc:74
      label: ABCG2
  - preferred_term: SLC2A9
    term:
      id: hgnc:13446
      label: SLC2A9
  - preferred_term: SLC22A12
    term:
      id: hgnc:17989
      label: SLC22A12
  modeled_mechanisms:
  - target: Hyperuricemia
    description: >-
      Serum urate is the model's single state; it rises above the ~6.8 mg/dL
      solubility limit under reduced fractional excretion (ABCG2 loss, low f_exc)
      or increased purine load (HPRT1 loss, PRPS1 superactivity), and is lowered
      by xanthine-oxidase inhibitors, uricosurics, and uricase.
  evidence:
  - reference: PMID:29904633
    reference_title: "Physiology of Hyperuricemia and Urate-Lowering Treatments."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      a progressive metabolic disease characterized by symptomatic hyperuricemia
      and deposition of monosodium urate (MSU) crystals in joints and soft
      tissues due to an imbalance in uric acid uptake, synthesis or excretion
    explanation: >-
      Establishes the production-versus-excretion imbalance that this
      single-compartment urate-balance model encodes.
  findings:
  - statement: >-
      The monosodium-urate solubility limit (~6.8 mg/dL) defines the
      hyperuricemia threshold used for this model's Hyperuricemia phenotype
      mapping.
    evidence:
    - reference: PMID:29904633
      reference_title: "Physiology of Hyperuricemia and Urate-Lowering Treatments."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The solubility of uric acid at normal physiological pH is generally
        given as 6.8 mg/dL
      explanation: >-
        Provides the 6.8 mg/dL urate solubility limit used as the model's
        Hyperuricemia activation threshold.
  notes: >-
    Wired for dismech-perturb (models/urate_homeostasis.config.yaml; Antimony
    source models/urate_homeostasis.ant). The disease-severity dial is fractional
    excretion f_exc (baseline 1.0 = normal). Treatment scenarios model allopurinol
    and febuxostat (xanthine-oxidase inhibition, XO down), probenecid (uricosuric,
    f_exc up), and pegloticase (recombinant uricase, k_uricase up), plus a
    combination. URAT1/GLUT9 loss-of-function raise excretion (renal hypouricemia,
    protective), while ABCG2 loss lowers it. Thresholds use the ~6.8 mg/dL urate
    solubility limit; other bands are model-calibrated.
  variables:
  - name: Serum_Urate
    dataset_identifier: U
    description: >-
      Serum urate (uric acid) concentration at steady state; the balance of
      production and elimination.
    unit: mg/dL
    mappings_list:
    - preferred_term: Hyperuricemia
      description: >-
        Serum urate above the monosodium-urate solubility limit (~6.8 mg/dL),
        the point of crystal-formation risk.
      term:
        id: HP:0002149
        label: Hyperuricemia
      threshold: 6.8
      threshold_direction: above
      severity_scale:
      - threshold: 6.8
        name: mild
      - threshold: 9.0
        name: moderate
      - threshold: 12.0
        name: severe
    - preferred_term: Hypouricemia
      description: >-
        Serum urate well below the normal ~5 mg/dL baseline, as in URAT1/GLUT9
        loss-of-function renal hypouricemia. Evaluated as a ratio to baseline.
      term:
        id: HP:0003537
        label: Hypouricemia
      threshold: 0.5
      threshold_direction: below
      severity_scale:
      - threshold: 0.5
        name: mild
      - threshold: 0.35
        name: moderate
      - threshold: 0.2
        name: severe
datasets:
references:
- reference: DOI:10.1007/s11606-024-08793-9
  title: 'Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin
    Comparative Effectiveness and SafEty (EMPRISE) Cohort Study'
  findings: []
- reference: DOI:10.1016/j.heliyon.2024.e38288
  title: 'Mechanism of macrophages in gout: Recent progress and perspective'
  findings: []
- reference: DOI:10.1038/s41598-024-74154-5
  title: Effective xanthine oxidase inhibitor urate lowering therapy in gout is
    linked to an emergent serum protein interactome of complement and
    inflammation modulators
  findings: []
- reference: DOI:10.1038/s42003-024-06534-6
  title: Unraveling the pathological biomineralization of monosodium urate
    crystals in gout patients
  findings: []
- reference: DOI:10.1093/rheumatology/keae420
  title: Association of rare and common genetic variants in <i>MOCOS</i> with
    inadequate response to allopurinol
  findings: []
- reference: DOI:10.1136/bmj-2024-080035
  title: 'Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for
    recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or
    gout: target trial emulation studies'
  findings: []
- reference: DOI:10.3389/fendo.2023.1071630
  title: Neutrophil autophagy induced by monosodium urate crystals facilitates
    neutrophil extracellular traps formation and inflammation remission in gouty
    arthritis
  findings: []
- reference: DOI:10.3390/gucdd2020016
  title: Regulation of Urate Homeostasis by Membrane Transporters
  findings: []
- reference: DOI:10.3390/ph17111507
  title: 'The Therapeutic Management of Chemical and Herbal Medications on Uric Acid
    Levels and Gout: Modern and Traditional Wisdom'
  findings: []
- reference: DOI:10.3390/pharmaceutics17010102
  title: 'Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment:
    Nanoparticles Delivery Systems Approach'
  findings: []
- reference: DOI:10.55563/clinexprheumatol/ezzfbt
  title: Mechanism of neutrophil extracellular traps in the pathogenesis of gout
  findings: []
- reference: DOI:10.7326/m23-0724
  title: Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors
    for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and
    Hospitalizations
  findings: []

📚

References & Deep Research

References

12

DOI:10.1007/s11606-024-08793-9

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study